Clinical Trials for Women’s Cancers
Medical College of Wisconsin physicians who specialize in gynecologic cancers collaborate with researchers and academic medical centers around the country to advance the understanding and treatment of ovarian, cervical, uterine, vulvar and vaginal cancers. Their patients – and the entire region – are the direct beneficiaries of on-going research.
The Gynecologic Cancer Program is an active member of the Gynecologic Oncology Group (GOG), an organization that coordinates multi-center clinical trials to advance the treatment of gynecologic cancers. The program is also involved with the Radiation Therapy Oncology Group (RTOG). Both are cooperative research groups funded by the National Cancer Institute.
Our physicians are also working to establish a Women’s Health Research Initiative and a tissue bank to advance the understanding of female cancers.
Ongoing studies provide access to the best research has to offer in advanced treatments and improved quality of life.
The following clinical trials are open to enrollment.
|Type of Cancer||Protocol ID & Study Title|
|Cervical or Pre-Cancer||CerGE
Women who have been treated for cervical cancer may be eligible for a current study on genetic susceptibility to that cancer. Exposure to the human papillomavirus (HPV) can lead to cervical cancer, but it doesn’t always.
A Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV (Advaxis Immunotherapy to prevent Cervical recurrence)
Keywords: Cervical, ADXS11-001, Adjuvant, High risk, Locally Advanced, AIM2CERV, Phase 3
|Cervical||ADVAXIS ADXS 001-04
Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer
Keywords: Cervical, Recurrent, Metastatic, ADXS11-001, Randomized
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA, Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Keywords: Stage I/IIA Cervical Cancer
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: THE OUTBACK TRIAL
Keywords: Phase 3, Cervical Cancer, Chemotherapeutic Agent, Toxicity, Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexuality and Reproductive Issues, The Outback Trial
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Keywords: Randomized, Phase II, Cisplatin, Stage II-IVA
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Keywords: Endometrial, GOG-0286B, Phase II/III, Recurrent, Stage III, Stage IVA, Stage IVB
|Endometrial||T Regulatory Cells and DNA Methylation in Early Endometrial Cancer Before and After Treatment
A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with Bevacizumab, followed by Bevacizumab and secondary cytoreduction surgery in platinum-sensitive, recurrent ovarian, fallopian tube and peritoneal primary cancer
Keywords: Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
Can Diet and Exercise Modulate Ovarian, Fallopian Tube or Peritoneal Cancer Progression-Free Survival?
Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Weight Change, Healthy Lifestyle
|Ovarian, Peritoneal||GOG 281
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Keywords: Ovarian, Peritoneal, Randomized, Trametinib, Low-grade, Serous, Recurrent
|Ovarian||GOG 3005 A Phase 3 Placebo-
Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PRO00024744)
Keywords: Ovarian, Primary, Maintenance, Untreated, PARP Inhibitor, PARP, Veliparib, Serous
|Ovarian||GOG 3012 - TESARO
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Keywords: HRD-positive, advanced Ovarian, Niraparib, Randomized, Double-blind
A Phase 3, Multicenter, Randomized, Open-label Study Of Avelumab (MSB0010718C) Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum-resistant/Refractory Ovarian Cancer
Keywords: Ovarian, Platinum Resistant, Platinum Refractory, Avelumab, Randomized
|Ovarian||Celsion Gen-1 Phase I Neoadjuvant Ovarian
A Phase I Study of the Safety and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Keywords: Phase 1, Ovarian, Neoadjuvant
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Keywords: Phase III, Olaparib, Cediranib, Platinum-Based, Ovarian
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Keywords: Randomized, Cediranib, Olaparib, Ovarian, Platinum Resistant
A Phase I/II STUDY OF Ruxolitinib With Front-Line Neoadjuvant And Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Keywords: Ruxolitinib, Neoadjuvant, Epithelial Ovarian
|Ovarian||IIT-Uyar Merck 3475-250
Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer
Keywords: Suboptimal Cytoreduced, Ovarian, Pembrolizumab, First Line, Epithelial, Nonrandomized
|Ovarian||Janssen R&D Protocol ET743-OVC-3006
A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced Relapsed Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Keywords: Randomized, Open Label, Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Relapsed, Phase 3, Recurrent Ovarian Cancer, Doxil, Yondelis, BRCA, Platinum Sensitive, Third Line
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations
Keywords: BRCA1/2, Olaparib, Recurrent, Ovarian
A Phase III Randomized Trial of Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Keywords: Uterine, Sarcoma, Leiomyosarcoma.
Learn more about the Gynecologic Cancer Program on the Froedtert & the Medical College of Wisconsin website.